Results 181 to 190 of about 88,385 (210)
Some of the next articles are maybe not open access.
The oncology impact of highly active antiretroviral therapy
Journal of Oncology Pharmacy Practice, 2007Objective. To examine the impact of using highly active antiretroviral therapy (HAART) in a human immunodeficiency virus (HIV) infected population on the chemotherapy related costs of treating acquired immunodeficiency (AIDS)-related cancers. Methods.
Richard, Schlichemeyer +2 more
openaire +2 more sources
Highly Active Antiretroviral Therapy
PharmacoEconomics, 2012The advent of highly active antiretroviral therapy (HAART), including protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors, for the treatment of HIV infection has led to a dramatic decline of morbidity and mortality. The acquisition costs of HAART are substantial. However, these costs are partially offset by reduced inpatient care
P. Sendi +3 more
semanticscholar +3 more sources
Highly active antiretroviral therapy and cervical intraepithelial neoplasia
AIDS, 2002Highly active antiretroviral therapy (HAART) has improved HIV prognosis, but its effect on cervical intraepithelial neoplasia (CIN), which is associated with HIV, is uncertain. Among 71 HAART-treated women the prevalence of CIN before HAART was 55%. After a median of 10 months after starting HAART the prevalence had increased to 62% (P = 0.20); 13% of ...
Antonia L, Moore +5 more
openaire +2 more sources
Adherence Assessment to Highly Active Antiretroviral Therapy
AIDS Patient Care and STDs, 2001Adherence to highly active antiretroviral therapy (HAART) is the outcome of a dynamic process of clinical and behavioral interactions. This article reviews factors influencing this process and provides suggestions to enhance adherence to HAART. Interventions to improve adherence to HAART should combine efficacy of treatments with a strong patient ...
openaire +2 more sources
Therapeutic drug monitoring in highly active antiretroviral therapy
Expert Opinion on Drug Safety, 2010Despite the efficacy of combination antiretroviral therapy (ART), a large proportion of patients living with HIV/AIDS on ART does not achieve or maintain adequate virological suppression. Therapeutic drug monitoring (TDM) has been utilised to improve treatment outcomes of ART.The potential incorporation of TDM into the clinical HIV management is ...
Xia, Liu, Qing, Ma, Fujie, Zhang
openaire +2 more sources
Virologic and immunologic response to highly active antiretroviral therapy
Current HIV/AIDS Reports, 2002Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV
Lisa P., Jacobson +2 more
openaire +3 more sources
Factors Affecting Patient Adherence to Highly Active Antiretroviral Therapy
Annals of Pharmacotherapy, 2003OBJECTIVE: To determine the clinical and demographic variables related to adherence to highly active antiretroviral therapy (HAART) in patients treated in our hospital and identify the characteristics of nonadherent patients. METHODS: Outpatients receiving treatment with HAART (n = 283) were asked about variables related to adherence and to complete ...
Escobar, Ismael +5 more
openaire +3 more sources
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science, 1997D. Finzi +14 more
semanticscholar +1 more source
Highly active antiretroviral therapy and HIV transmission
The Lancet, 2006Julio Montaner and colleagues (Aug 5, p 531) postulate that the widespread use of highly active antiretroviral therapy (HAART) can decrease HIV incidence. They argue for a preventioncentred expansion in the use of HAART, and argue that the transmission benefi t is unlikely to be outweighed by increases in sexual risk behaviour. In one of the ecological
openaire +1 more source